|Bid||N/A x N/A|
|Ask||N/A x N/A|
|Day's Range||N/A - N/A|
|52 Week Range||undefined - undefined|
|Beta (3Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
On January 29, Sanofi announced its acquisition of Ablynx for $4.8 billion, and it announced the completion of the acquisition on June 19. The acquisition was one of two announced in January to advance its blood disorder portfolio. The other acquisition was of Bioverative.
Small and large cap stocks are widely popular for a variety of reasons, however, mid-cap companies such as Ablynx NV (EBR:ABLX), with a market cap of €3.38b, often get neglectedRead More...
The most recent earnings release Ablynx NV’s (ENXTBR:ABLX) announced in December 2017 suggested that losses became smaller relative to the prrior year’s level – great news for investors Below, I’veRead More...